Review
Copyright ©The Author(s) 2022.
World J Gastroenterol. Oct 7, 2022; 28(37): 5403-5419
Published online Oct 7, 2022. doi: 10.3748/wjg.v28.i37.5403
Table 3 Overview of Immunotherapy-based novel nanoparticles in the treatment of colorectal cancer [PubMed Search (immunotherapy) AND (nanoparticle) AND (colorectal cancer)]
Type of nanoparticle
Treatment strategy
Drugs or active substance involved
The main involvement of immune cells
Ref.
CopolymersPDT induces HIF-1α expression, leading to the upregulation of PD-L1 expression, ICIsPhotosensitizer, PD-L1 antibodyDCs, CD8+T cells, memory T cellsYuan et al[107]
Polymeric nanoparticlePTT, chemotherapy, ICDPBOXA, donor–spacer–acceptor–spacer–donor type fluorophoreDCs, T cells, CTLsZhu et al[108]
CopolymersICD, ICIsSK, PD-L1 knockdown siRNADCs, TAMs, Tregs, T cellsLi et al[109]
PolymersICD, ferroptosisDHADCs, T cellsDuan et al[111]
Platelet membrane-coated nanoparticleTLR7 treatmentR848DCsBahmani et al[113]
Liposomes with cell membraneICD, chemotherapy, lncRNA-targeting therapyOxaliplatin, shPvt1DCs, MDSCs, CD8+T cellsLiu et al[117]
Silver nanoparticlesAnti-FnPhage M13MDSCs, DCs, TAMsDong et al[122]
Supramolecular assembled programmable immune activation nanomedicineIn-situ cancer vaccine, ICDPPCD, CpG/PAMAMDCs, CD8+T cellsZhang et al[123]